RETRACTED ARTICLE: Inter- and intraobserver agreement of the quantitative assessment of [(99m)Tc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer

PURPOSE: Checkpoint inhibition therapy using monoclonal antibodies against programmed cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small cell lung cancer (NSCLC). PD-L1 expression is a validated and approved prognostic and predictive biomarker for anti-PD-1/PD-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Daniel Johnathan, Chand, Gitasha, Goh, Vicky, Cook, Gary J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708592/
https://www.ncbi.nlm.nih.gov/pubmed/33259032
http://dx.doi.org/10.1186/s13550-020-00734-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708592/
https://www.ncbi.nlm.nih.gov/pubmed/33259032
http://dx.doi.org/10.1186/s13550-020-00734-x

Ejemplares similares